The Mereo-partnered drug is in pivotal development for osteogenesis imperfecta. Ultragenyx also recently reported positive Phase III data for a rare disease gene therapy.

Deal Snapshot: Agios sold rights to a 15% royalty on US net sales of the IDH1/2 inhibitor vorasidenib, which it sold to Servier in 2020.

Public Company Edition: Cytokinetics executed a royalty financing deal for up to $575m and grossed $500m in a follow-on offering. Also, GSK grossed £1.25bn ($1.58bn) in sale of final Haleon shares, Bicycle raised $555m in a private placement and Apellis accessed up to $475m in debt.

Private Company Edition: Attovia will advance two anti-IL-31 programs with its $105m in series B funding, while ImmuNext secured $575m in a Royalty Pharma deal for its Sanofi-partnered drug. Also, Bluejay and Aardvark raised $182m and $85m, respectively, in series C rounds.